NatiVita, as international biotechnology pharmaceutical company, is confident that entrepreneurship in combination with research and development will drive the innovation. The most efficient and proven model, in which entrepreneurs can strive is the venture capital model. As NatiVita is specialized in cancer diseases, we bring in-depth knowledge and an international network.
WHY TO INVEST IN NATIVITA
Unique for Belarus R&D and manufacturing facilities open for an investor the Eurasian Economic Union pharmaceutical market (Belarus, Russia, Kazakhstan, Armenia and Kyrgyzstan) with:
- 200 million people
- 20 billion dollars pharmaceutical market turnover
- Preferences for local pharmaceutical manufacturers15% for governmental procurement system and non – admission to procurement of foreign producers in the event of two or more local manufacturers
WHY TO INVEST WITH NATIVITA
NatiVita is the successful investment project that allowed the company to become No1 in oncology of the Republic of Belarus. NatiVita is ready to share unique expertise on starting up an innovative pharmaceutical business as a joint venture or on the basis of a franchise agreement.